The US Federal Food & Drug Department recently gave approval to Tirzepatide as a weight management drug. Eli Lilly’s weight loss drug is on board, selling the drug under the new name Zepbound.
Tirzepatide is traditionally used to treat type 2 diabetes. The drug is now already being sold as an off-label prescription for weight loss.
Several studies showed that the drug holds more than the average dose of weight loss. Making it 20% more effective than any other weight management drug. Only if given in a higher dose for 72 weeks.
FDA’s approval for the drug includes prescriptions for life-threatening obesity or even those medically characterized as overweight.
The Eli Lilly weight loss drug was initially called Mounjaro when it was only classified as a diabetic medicine. However, now, with a prescription, you can buy Tirzepatide in the name of Zepbound.
The creator of Zepbound is Eli Lilly, and this will be their new class of drugs, which will include the Semaglutide called Ozempic and Wegovy.
Ozempic is popularly known for treating diabetes. While Wegovy is solely for weight loss, both these drugs have had a skyrocketing popularity recently. Especially in the celebrity sphere.
While many believe the usage of such drugs isn’t always authentic for everyone. However, this FDA-approved drug in the form of Zepbound should only be prescribed and sold to patients in absolute need. Claimed the makers.
“Overweight and Obesity are not a matter of status, but serious diseases which can cause heart conditions, arthritis, and other serious conditions. It is the leading cause of diabetes, and heart attack in the USA”, said Dr. John Sharretts, who is the FDA director in the department’s Diabetes, Lipid Disorder, and Obesity section. (Source)
He also added his concern with the rising rate of obesity in the country and how there is a serious medical need to eradicate it.
Side effects of Eli Lilly’s weight loss drug Zepbound include vomiting, nausea, diarrhea, and gastrointestinal issues. The label will also include some of the serious issues.